ITCI:NGS-Intra-Cellular Therapies Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | Nasdaq Global Select

Last Closing

USD 67.3

Change

+0.30 (+0.45)%

Market Cap

USD 0.57B

Volume

0.81M

Analyst Target

USD 45.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is engaged in discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

-0.81 (-0.59%)

USD 13.58B
VTRS Viatris Inc

-0.22 (-2.12%)

USD 12.47B
LNTH Lantheus Holdings Inc

-0.82 (-1.02%)

USD 5.60B
ALKS Alkermes Plc

-0.31 (-1.25%)

USD 4.20B
ALVO Alvotech

-0.23 (-1.61%)

USD 3.99B
HCM HUTCHMED DRC

-0.52 (-2.79%)

USD 3.17B
INDV Indivior PLC Ordinary Shares

+0.24 (+1.47%)

USD 2.47B
DCPH Deciphera Pharmaceuticals LLC

N/A

USD 2.21B
AMPH Amphastar P

-0.14 (-0.34%)

USD 1.99B
EVO Evotec SE ADR

-0.01 (-0.22%)

USD 1.74B

ETFs Containing ITCI

PSIL AdvisorShares Psychedelic.. 5.65 % 0.00 %

N/A

USD 5.92M
XPH SPDR® S&P Pharmaceutical.. 4.94 % 0.35 %

-0.53 (-1.40%)

USD 0.20B
IBRN iShares Trust - iShares N.. 4.49 % 0.00 %

-0.33 (-1.40%)

USD 3.84M
VRTGX Vanguard Russell 2000 Gro.. 0.58 % 0.00 %

-5.60 (-1.40%)

USD 1.19B
VTWG Vanguard Russell 2000 Gro.. 0.58 % 0.20 %

-2.88 (-1.40%)

USD 0.91B
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

-0.23 (-1.40%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.03% 51% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.03% 51% F 39% F
Trailing 12 Months  
Capital Gain 10.33% 69% C- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.33% 69% C- 60% D-
Trailing 5 Years  
Capital Gain 399.63% 98% N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 399.63% 98% N/A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 53.86% 86% B+ 91% A-
Dividend Return 53.86% 86% B+ 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.84% 49% F 32% F
Risk Adjusted Return 103.90% 100% F 98% N/A
Market Capitalization 0.57B 97% N/A 91% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 10.78 12% 11%
Price / Cash Flow Ratio -56.38 100% 94%
Price/Free Cash Flow Ratio -37.12 96% 93%
Management Effectiveness  
Return on Equity -18.07% 58% 45%
Return on Invested Capital -25.65% 45% 31%
Return on Assets -11.23% 41% 32%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.